be careful
This stock has been undervalued for so long for a good reason maybe. betting on fda may still be too far away. a second phase 3 trail might be in the works imo. Just because its the only bladder drug to be developed in a while doesnt make it a winner. traded for months well below fair value and seems like traders are in to make a quick buck. back to .37. hope im wrong